Abstract
No public abstract is available from the verified source records.
Zhidi He, Yulin Xu, Zhipeng Tian, Ziyan Dong, Shiyu Zhu, Rong Guo, Bing Xiang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Shear stress-mediated adhesion of acute myeloid leukemia and KG-1 cells to endothelial cells involves functional P-selectin
10.1089/scd.2008.0380 · 2009
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias
10.1016/j.ctrv.2020.102026 · 2020
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
10.23736/s0026-4806.20.07017-2 · 2020
Extracellular vesicle-hitchhiking nanoliposomes for cancer-associated fibroblast phenotype modulation impede metastasis progression
2025
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
10.1080/13543784.2019.1694661 · 2019
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
10.1182/bloodadvances.2018027409 · 2019
Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces
10.1016/j.biomaterials.2013.11.011 · 2014
unpaywall
Confidence 95%
datacite
Confidence 0%
Dual-targeted self-delivery micelle co-loading doxorubicin and artesunate for enhanced AML treatment via mitochondrial damage induction
10.26599/nr.2025.94907663 · 2025
Bone marrow microenvironment-targeted yolk-shell nanoparticle enhances acute myeloid leukemia chemotherapy by preventing endothelial cell/ ECM-mediated adhesion
10.1016/j.cej.2025.164084 · 2025
10.1038/s41586-023-05812-3
10.1038/s41586-023-05812-3
Smart and generalizable cytarabine derivative-triggered nanoparticles for synergistic therapy of relapsed/refractory acute myeloid leukemia
10.1021/acsami.3c03632 · 2023
Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting
10.1016/j.biomaterials.2025.123091 · 2025
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
10.1038/nm1483 · 2006
Genetic abnormalities and challenges in the treatment of acute myeloid leukemia
10.1177/1947601911408076 · 2011
Shield and sword nano-soldiers ameliorate rheumatoid arthritis by multi-stage manipulation of neutrophils
10.1016/j.jconrel.2021.05.008 · 2021
Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery
10.1038/s41467-024-50021-9 · 2024
Nanoparticle-mediated “cut-off and clean-up” strategy for neutrophil manipulation in acute lung injury therapy
10.1021/acsnano.5c09856 · 2025
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer's disease therapy
10.1038/s41392-025-02453-y · 2025
Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials
10.3389/fphar.2019.00697 · 2019
The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
2021
Co-delivery of daunorubicin and homoharringtonine in folic acid modified-liposomes for enhancing therapeutic effect on acute myeloid leukemia
10.1016/j.xphs.2022.04.014 · 2023
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use
10.1002/ajh.25369 · 2019
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia
10.1158/2159-8290.cd-13-0609 · 2014
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
10.1158/2159-8290.cd-19-0710 · 2020
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3
10.1016/j.cell.2008.03.037 · 2008
Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway
10.1016/j.bcp.2021.114538 · 2021
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia
10.1007/s10637-025-01541-8 · 2025
All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase
10.1016/j.canlet.2019.12.045 · 2020
Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia
10.1016/j.actbio.2022.11.007 · 2023
Acute promyelocytic leukemia: from highly fatal to highly curable
10.1182/blood-2007-07-102798 · 2008
Targeting mitochondrial proteases for therapy of acute myeloid leukaemia
10.1111/bph.15844 · 2022
Identifying effective drug combinations for patients with acute myeloid leukemia
10.1080/14737140.2020.1782749 · 2020
Venetoclax enhances DNA damage induced by XPO1 inhibitors: a novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia
10.1111/jcmm.17274 · 2022
Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia
10.1016/j.leukres.2014.08.020 · 2014
The therapeutic synergy of selinexor and venetoclax in mantle cell lymphoma through induction of DNA damage and perturbation of the DNA damage response
10.1177/15330338231208608 · 2023
Neutrophil/leukemia-tropic dual-drug nanomedicine potentiates the treatment of acute myeloid leukemia
10.1002/adma.202512635 · 2026
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
2023
Antibody-mediated ratiometric delivery of FLT3 and CDK4/6 dual inhibitors for targeted treatment of acute myeloid leukemia
10.1016/j.jconrel.2025.113934 · 2025
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
10.1038/s41419-022-04810-z · 2022
Redox dual-responsive dendrimeric nanoparticles for mutually synergistic chemo-photodynamic therapy to overcome drug resistance
10.1016/j.jconrel.2020.10.048 · doi-reference
Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells
10.1016/j.cbi.2023.110740 · doi-reference
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
10.18632/oncotarget.9185 · doi-reference
Roles of Chk1 in cell biology and cancer therapy
10.1002/ijc.28226 · doi-reference
A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy
10.1038/s41565-024-01736-9 · doi-reference
Nanomedicine of synergistic drug combinations for cancer therapy - strategies and perspectives
10.1016/j.jconrel.2016.06.012 · doi-reference